Search

Your search keyword '"Carpinelli, Patrizia"' showing total 35 results

Search Constraints

Start Over You searched for: Author "Carpinelli, Patrizia" Remove constraint Author: "Carpinelli, Patrizia"
35 results on '"Carpinelli, Patrizia"'

Search Results

2. Supplementary Fig. S1 from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer

3. Supplementary Table S1 from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer

5. Supplementary Table 1 from Crystal Structure of the T315I Abl Mutant in Complex with the Aurora Kinases Inhibitor PHA-739358

9. Thieno[3,2- c]pyrazoles: A novel class of Aurora inhibitors with favorable antitumor activity

10. PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc

11. A Focused Small-Molecule Screen Identifies PHA-680626 as an Amphosteric Inhibitor Disrupting the Interaction between Aurora-A and N-Myc

13. Cloning and overexpression in Escherichia coli of the genes encoding NAD-dependent alcohol dehydrogenase from two Sulfolobus species

14. Abstract 3795: Novel and selective MELK kinase inhibitors active in breast cancer cell lines

16. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.

20. Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors

22. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer

23. Crystal Structure of the T315I Abl Mutant in Complex with the Aurora Kinases Inhibitor PHA-739358

24. 1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: Identification of a Potent Aurora Kinase Inhibitor with a Favorable Antitumor Kinase Inhibition Profile

25. PHA-680632, a Novel Aurora Kinase Inhibitor with Potent Antitumoral Activity

26. Potent and Selective Aurora Inhibitors Identified by the Expansion of a Novel Scaffold for Protein Kinase Inhibition

27. Aurora Kinases and Their Inhibitors: More Than One Target and One Drug.

32. Aurora kinase inhibitors: identification and preclinical validation of their biomarkers

33. Combined cisplatin and aurora inhibitor treatment increase neuroblastoma cell death but surviving cells overproduce BDNF

34. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.

35. Is there a future for Aurora kinase inhibitors for anticancer therapy?

Catalog

Books, media, physical & digital resources